CELL LINE DEVELOPMENT MARKET ANALYSIS

Market Challenges And Opportunities

Collaborations by cell line development companies with drug discovery companies to speed up expansion of cell line development market

Some of the major players operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures , Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells. These companies are entering into strategic partnership with drug discovery companies to optimize their product development:

• In December 2017, Selexis SA and Turgut Pharmaceuticals announced to enter into a third commercial license agreement, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.
• In April 2017, CBMG entered into a partnership with GE Healthcare for the manufacture of stem cells used in cell line development.
• In January 2018, PX’Therapeutics announced collaboration with biotech firm Advaxis for process development of immunotherapies of Advaxis
• In February 2018, Denali Therapeutics entered into a partnership with Lonza to develop and produce biologic medicines using the latter’s cell line development technology GS Xceed.
• Industry players are focusing towards expanding business portfolio to consolidate their market position as well as increase consumer base. For instance, in February 2017, Lonza entered into strategic partnership with Sanofi, which aimed at building mammalian cell facilities to produce monoclonal antibodies in Switzerland.